Phosphoinositide 3-kinase in Health and Disease

Volume 2

  • Christian Rommel
  • Bart Vanhaesebroeck
  • Peter K. Vogt

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 347)

Table of contents

  1. Front Matter
    Pages i-x
  2. Bart Vanhaesebroeck, Peter K. Vogt, Christian Rommel
    Pages 1-19
  3. Yardena Samuels, Todd Waldman
    Pages 21-41
  4. Sandra B. Gabelli, Chuan-Hsiang Huang, Diana Mandelker, Oleg Schmidt-Kittler, Bert Vogelstein, L. Mario Amzel
    Pages 43-53
  5. Peter K. Vogt, Jonathan R. Hart, Marco Gymnopoulos, Hao Jiang, Sohye Kang, Andreas G. Bader et al.
    Pages 79-104
  6. Krishna M. Vasudevan, Levi A. Garraway
    Pages 105-133
  7. Caterina Nardella, Arkaitz Carracedo, Leonardo Salmena, Pier Paolo Pandolfi
    Pages 135-168
  8. Saveur-Michel Maira, Peter Finan, Carlos Garcia-Echeverria
    Pages 209-239
  9. Zachary A. Knight
    Pages 263-278
  10. Back Matter
    Pages 297-304

About this book


From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here


PDK1 PIK3 TOR kinase domain inhibitor haematological malignancies malignant glioma oncogenesis oncoprotein

Editors and affiliations

  • Christian Rommel
    • 1
  • Bart Vanhaesebroeck
    • 2
  • Peter K. Vogt
    • 3
  1. 1.IntellikineLa JollaUSA
  2. 2., Institute of Cancer and the London SchooQueen Mary, University of LondonLondonUnited Kingdom
  3. 3., Dept. Molecular & Exp. MedicineScripps Research InstituteLa JollaUSA

Bibliographic information